findmyKOL

Jared Weiss, MD

Enriched profile

Section Chief of Thoracic and Head/Neck Oncology; Professor of Medicine · University of North Carolina at Chapel Hill

ORCIDNone on fileNPI
Region🇺🇸 Chapel Hill, NC · Southeast · United StatesSpecialtyHematology / OncologyFocusGastroesophageal Cancer+2
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2025NIH funding2025–2026Why? →

Jared Weiss is Section Chief of Thoracic and Head/Neck Oncology; Professor of Medicine at University of North Carolina at Chapel Hill. ClinicalTrials.gov lists 17 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 2 Sept 2026

Jared Weiss, MD, is Section Chief of Thoracic and Head/Neck Oncology at University of North Carolina at Chapel Hill / UNC Lineberger Comprehensive Cancer Center. The public record shows 96 publications with 6,955 citations (h-index 32), centered on Gastroesophageal Cancer, Lung Cancer (NSCLC/SCLC), Head & Neck Cancer. It also documents an investigator role on 17 registered clinical trials, industry payments reported by 29 companies, 1 NIH-funded awards (2025–2026).

  • Top research focus: Gastroesophageal Cancer
  • 17 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 29 companies

Generated from the cited public record · current as of 2 Sept 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)9 trialsHead & Neck Cancer7 trialsSmall Cell Lung Carcinoma7 trialsCarcinoma, Squamous Cell4 trialsGastroesophageal Cancer1 trialEsophageal Neoplasms1 trialMouth Neoplasms1 trialOropharyngeal Neoplasms1 trialLaryngeal Neoplasms1 trialLip Neoplasms1 trialRecurrence1 trialPleural Effusion1 trialPleural Effusion, Malignant1 trial

Research focus

OpenAlex concept fingerprint
Gastroesophageal CancerLung Cancer (NSCLC/SCLC)Head & Neck Cancer

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trialsIndustry payments9PublicationsCoselageneric · TrilaciclibClinical trialsIndustry payments7PublicationsTecentriqgeneric · AtezolizumabClinical trialsIndustry payments3Publications

Works with

trial sponsors and companies reporting payments
UNC Lineberger Comprehensive Cancer CenterClinical trials16Industry paymentsMerck Sharp & Dohme LLCClinical trialsIndustry payments11EMD Serono, Inc.Clinical trialsIndustry payments8

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
32h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
17clinical trials

Investigator role on registered studies.

View trials
29companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2025–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 2 Sept 2026

Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:

14 more trial records behind the reveal.Reveal →

Industry payments

Updated 2 Sept 2026

29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Hormonal (systemic)

    31.5%
    l-Thyroxine31.5%
    Levothyroxine Sodium100%
    Part D14 patients
  • Nervous system

    18.4%
    Atypical Antipsychotic9.4%
    Olanzapine100%
    Part D18 patients
    Phenothiazine9%
    Prochlorperazine Maleate100%
    Part D18 patients
  • Cancer & immunology

    17.2%
    Kinase inhibitor17.2%
    Tagrisso100%
    Part D<11 patients
4 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)92.8% facility · 7.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 2 Sept 2026

1 NIH research award on record, funded 20252026 per NIH RePORTER. The latest:

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Background & recognition

Updated 2 Sept 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Hematology/Oncology Fellowship

    Hospital of the University of Pennsylvania, 2007-2010

    2010
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rmei.com
  • Board Certified

    Internal Medicine (2007), Medical Oncology (2010), and Hematology

    2010
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.unc.edu
  • MD

    Yale University School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • BS

    Neuroscience, Brown University

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • Internal Medicine Residency

    Beth Israel Deaconess Medical Center, Harvard

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu

Editorial & leadership roles

journal and society appointments
  • Section Chief

    Thoracic and Head/Neck Oncology, UNC School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unclineberger.org
  • Member

    Cancer Therapeutics Research Program, UNC Lineberger

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unclineberger.org
  • Member

    Thoracic Oncology Program, UNC Lineberger

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unclineberger.org
4 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
2 more awards behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.